Amundi
NRIX icon

Amundi’s Nurix Therapeutics NRIX Stock Holding History

Amundi’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17
Closed -$179 – 2005
2025
Q1 		$179 Hold
17
– – ﹤0.01% 2166
2024
Q4 		$332 Buy
+17
New +$390 ﹤0.01% 2130
2024
Q2 		– Sell
-43,755
Closed -$632K – 2008
2024
Q1 		$632K Hold
43,755
– – ﹤0.01% 1373
2023
Q4 		$427K Buy
+43,755
New +$300K ﹤0.01% 1461
2022
Q1 		– Sell
-5,113
Closed -$113K – 1697
2021
Q4 		$113K Buy
5,113
+4,499
+733% +$136K ﹤0.01% 1558
2021
Q3 		$18K Buy
+614
New +$18.9K ﹤0.01% 1551

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amundi's NRIX Position: Q2 2025 in Review

Amundi sold out of Nurix Therapeutics (NRIX) in Q2 2025, closing a stake of 17 shares — an estimated $179 sold.

Amundi first reported a position in NRIX in Q3 2021 and held it in 6 quarters. The position peaked at $632K in Q1 2024. 163 funds tracked by Wall St. Rank hold NRIX as of Q2 2025.

  • Amundi reported no remaining Nurix Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 17 Nurix Therapeutics shares in Q2 2025, an estimated $179.
  • Amundi first reported a position in Nurix Therapeutics in Q3 2021 and held it in 6 quarters.
  • Amundi's Nurix Therapeutics position peaked at $632K in Q1 2024.
  • 163 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.